ClinicalTrials.Veeva

Menu
A

AA Medical Research Center | Flint, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

sodium
Povorcitinib
Inclisiran
VX-147
Tirzepatide
Finerenone
LY3298176
Verekitug
UPB-101

Parent organization

This site is a part of AA Medical Research Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo
Locations recently updated

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Novartis logo
Bayer logo
Incyte logo
Lilly logo
U
Vertex Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems